Sponsor
Tesaro, Inc.
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Tesaro, Inc. appears in 17 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
17 shownStudy Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast CancerNCT03329937 · lead sponsor · 2018-04-12
COMPLETEDStudy of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042NCT03307785 · lead sponsor · 2017-10-12
COMPLETEDEffects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer ParticipantsNCT03308942 · lead sponsor · 2017-09-29
COMPLETEDStudy of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid TumorsNCT03250832 · lead sponsor · 2017-08-08
COMPLETEDA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)NCT02817633 · lead sponsor · 2016-07-08
ACTIVE_NOT_RECRUITINGNiraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerNCT02657889 · lead sponsor · 2016-04-15
COMPLETEDStudy of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsNCT02715284 · lead sponsor · 2016-03-07
ACTIVE_NOT_RECRUITINGA Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer PatientsNCT01905592 · lead sponsor · 2014-02-25
TERMINATEDA Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and LymphomasNCT02048488 · lead sponsor · 2012-10-01
COMPLETEDA Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)NCT00749502 · lead sponsor · 2008-09-01
COMPLETEDLCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast CancerNCT04762901 · collaborator · 2021-04-01
WITHDRAWNNiraparib in Combination With Trastuzumab in Metastatic HER2+ Breast CancerNCT03368729 · collaborator · 2019-09-06
ACTIVE_NOT_RECRUITINGA Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer PatientsNCT03945721 · collaborator · 2019-07-11
ACTIVE_NOT_RECRUITINGNiraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung CancerNCT03891615 · collaborator · 2019-06-06
TERMINATEDNiraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line ChemotherapyNCT03830918 · collaborator · 2019-03-06
ACTIVE_NOT_RECRUITINGA Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer PatientsNCT02826512 · collaborator · 2018-05-15
TERMINATEDEnzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)NCT02500901 · collaborator · 2016-03-01
TERMINATEDSponsor roles
lead sponsor10
collaborator7
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.